Myotonic Dystrophy is an autosomal dominantly inherited multisystem disorder (MD type 1 and MD type 2). The main objective of forming a disease-oriented biobank is the structured storage of biomaterial and clinical data, both for research purposes within the Radboudumc and for (inter)national collaborations in the future. For both MD1 and MD2, investigation of DNA and pathophysiological mechanisms will be an important objective, with identification of targets for therapy.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items

National Biobanks & Collections day
19 October 2023The Health-RI Biobanks & Collections workgroup proudly announces the first National Biobanks & Collections Day. The meeting will take place on November 9 in Amsterdam.
read more
Quality certificate for the PBMC isolation method and cfDNA extraction method
8 August 2023Last year the Radboud Biobank participated for the first time in the IBBL Biospecimen Proficiency Testing program; an external quality assessment tool to verify the precision and accuracy of biospecimen testing methods and the efficiency of processing methods.
read more
TETRO-trial
30 March 2023The TETRO-trial is a study on a new treatment for compulsive/obsessive-compulsive disorder.
read more
Archipelago
30 March 2023Archipelago of Ovarian Cancer Research (AOCR) is a national platform for centralizing and expanding scientific research into ovarian cancer.
read more
Theme Biobank and collections of Health RI launched a new project to develop a novel Dutch Biobank Standard
30 March 2023In February 2023 the theme Biobanks and Collections of Health-RI launched a new project entitled: “Dutch biobanking standard: towards harmonized, evidence-based collection, processing and storage of human biomaterials”.
read more
Health-RI receives definitive follow-up funding from the National Growth Fund
30 March 2023The full funding of a total of 69 million euros has been definitively awarded to Health-RI, the national health data infrastructure for research and innovation.
read more